<DOC>
	<DOCNO>NCT01009047</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety extended-release ( ER ) paliperidone compare aripiprazole ( atypical antipsychotic ) symptomatic ( symptom ) adolescent participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusions hallucination [ imagine thing ] , withdrawal self ) .</brief_summary>
	<brief_title>An Efficacy Safety Study Extended-Release ( ER ) Paliperidone Adolescent Participants With Schizophrenia</brief_title>
	<detailed_description>This multi-center ( conduct 1 center ) , double-blind ( neither physician participant know name assigned drug ) , randomize ( study drug assign chance ) , active-controlled ( paliperidone ER compare aripiprazole ) , parallel-group ( medical research study compare response 2 group participant receive different treatment ) , flexible-dose ( physician freedom give different dos participant depend respond treatment ) study design determine efficacy safety paliperidone ER symptomatic adolescent ( 12 17 year age ) schizophrenia . The total duration study approximately 29 week . The study consist 3 phase : Screening phase 3 week ( possible overlap washout period ) , Double-blind acute phase 8 week , Double-blind maintenance phase 18 week . Participants randomly assign 1 2 treatment group ( paliperidone ER aripiprazole flexible oral dos ) . Dosage adjust schedule visit . Efficacy participant primarily evaluate Positive Negative Syndromes Scale ( PANSS ) . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Participants must currently meet Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIV ) criteria schizophrenia experience symptom illness least 1 year , least treatment 1 antipsychotic participation study Participants Positive Negative Syndromes Scale ( PANSS ) score 60 120 inclusive Screening Female participant must incapable pregnancy , heterosexually active capable pregnancy , use acceptable method contraception least 1 month study entry agree continue use contraception method duration study , sexually abstinent ( sexual intercourse ) capable pregnancy , must agree continue abstinence use acceptable method birth control Participants must danger others , must family support available maintain outpatient Participants weight equal great 29 kilogram Participants mild ( serious ) , moderate ( medium level seriousness ) , severe ( serious , life threaten ) mental retardation Participants know suspected history substance dependence ( include alcohol , exclude nicotine caffeine ) per DSMIV criterion 3 month Screening Participants history certain neurological ( pertain nervous system ) disorder insulindependent diabetes mellitus ( disorder decrease insulin body body 's insulin effective , result high blood sugar , increase thirst urine , many side effect ) Participants receive depot injectable antipsychotic within 2 treatment cycle Screening visit Participants receive clozapine 2 month Baseline visit ( Day 1 Week 1 )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone</keyword>
	<keyword>Aripiprazole</keyword>
</DOC>